Ohlman S - Search Results

1

A Randomized, Phase II Study Evaluating the Efficacy and Safety of Anakinra in the Treatment of Gout Flares.

Saag KG, Khanna PP, Keenan RT, Ohlman S, Osterling Koskinen L, Sparve E, Åkerblad AC, Wikén M, So A, Pillinger MH, Terkeltaub R. Saag KG, et al. Among authors: ohlman s. Arthritis Rheumatol. 2021 Aug;73(8):1533-1542. doi: 10.1002/art.41699. Epub 2021 Jul 7. Arthritis Rheumatol. 2021. PMID: 33605029 Free article. Clinical Trial.

2

Anakinra in children and adults with Still's disease.

Vastert SJ, Jamilloux Y, Quartier P, Ohlman S, Osterling Koskinen L, Kullenberg T, Franck-Larsson K, Fautrel B, de Benedetti F. Vastert SJ, et al. Among authors: ohlman s. Rheumatology (Oxford). 2019 Nov 1;58(Suppl 6):vi9-vi22. doi: 10.1093/rheumatology/kez350. Rheumatology (Oxford). 2019. PMID: 31769856 Free PMC article. Review.

3

A randomized pilot study of cyclosporin G in renal transplantation.

Ohlman S, Lindholm A, Gäbel H, Wilczek H, Tydén G, Reinholt F, Säwe J, Groth CG. Ohlman S, et al. Transpl Int. 1992;5 Suppl 1:S464-9. doi: 10.1007/978-3-642-77423-2_136. Transpl Int. 1992. PMID: 14621848 Clinical Trial.

4

The impact of acute rejection episodes on long-term graft function and outcome in 1347 primary renal transplants treated by 3 cyclosporine regimens.

Lindholm A, Ohlman S, Albrechtsen D, Tufveson G, Persson H, Persson NH. Lindholm A, et al. Among authors: ohlman s. Transplantation. 1993 Aug;56(2):307-15. doi: 10.1097/00007890-199308000-00010. Transplantation. 1993. PMID: 8356584 Clinical Trial.

5

Rejection associated with early appearance of donor-reactive antibodies after kidney transplantation treated with plasmapheresis and administration of 15-deoxyspergualin. A report of two cases.

Gannedahl G, Ohlman S, Persson U, Gudmundsson S, Larsson E, Tydén G, Tötterman TH, Wikström B, Weiss L, Groth CG, et al. Gannedahl G, et al. Among authors: ohlman s. Transpl Int. 1992 Sep;5(4):189-92. doi: 10.1007/BF00336067. Transpl Int. 1992. PMID: 1418307

6

Treatment of renal transplant rejection with 15-deoxyspergualin--a dose-finding study in man.

Ohlman S, Gannedahl G, Tydén G, Tufveson G, Groth CG. Ohlman S, et al. Transplant Proc. 1992 Feb;24(1):318-20. Transplant Proc. 1992. PMID: 1539294 Clinical Trial. No abstract available.

7

Pharmacokinetics of 15-deoxyspergualin studied in renal transplant patients receiving the drug during graft rejection.

Ohlman S, Zilg H, Schindel F, Lindholm A. Ohlman S, et al. Transpl Int. 1994;7(1):5-10. doi: 10.1007/BF00335656. Transpl Int. 1994. PMID: 8117404

8

On the intraindividual variability and chronobiology of cyclosporine pharmacokinetics in renal transplantation.

Ohlman S, Lindholm A, Hägglund H, Säwe J, Kahan BD. Ohlman S, et al. Eur J Clin Pharmacol. 1993;44(3):265-9. doi: 10.1007/BF00271369. Eur J Clin Pharmacol. 1993. PMID: 8491242

9

Effects of 15-deoxyspergualin on mononuclear cells from kidney recipients.

Johansson-Borg A, Ohlman S, Groth CG. Johansson-Borg A, et al. Among authors: ohlman s. Transplant Proc. 1992 Feb;24(1):267-8. Transplant Proc. 1992. PMID: 1539276 Clinical Trial. No abstract available.

10

New immunosuppressive drugs in transplantation.

Groth CG, Ohlman S, Gannedahl G, Ericzon BG. Groth CG, et al. Among authors: ohlman s. Transplant Proc. 1993 Aug;25(4):2681-3. Transplant Proc. 1993. PMID: 7689274 Review. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

19 results

Search Page